SOGUG-NEOWIN: A Phase 2, open-label, multi-centre, multi-national interventional trial evaluating the efficacy and safety of Erdafitinib (ERDA) monotherapy and ERDA and Cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with Muscle-Invasive Bladder Cancer (MIBC) whose tumours express FGFR gene alterations
医学
顺铂
内科学
肿瘤科
化疗
作者
Andrea Necchi,Syed A. Hussain,Yohann Loriot,Guillermo de Velasco
PDF的下载单位、IP信息已删除
(2025-6-4)
Kao
cx
OK
Nole
大力翠风
表弟慢热手
zzzz
rest
美满的访旋
skearthy
大力的冬萱
YifanWang
嘻嘻哈哈
Criminology34
文Bo博
学术文献互助
Oracle
Copyright
云云逸云
null
皖公网安备34019202002308
